Assessment of Parkinson Disease Manifestations

Joel S. Perlmutter1

1 Washington University School of Medicine in St. Louis, St. Louis, Missouri
Publication Name:  Current Protocols in Neuroscience
Unit Number:  Unit 10.1
DOI:  10.1002/0471142301.ns1001s49
Online Posting Date:  October, 2009
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

Parkinson disease (PD) is a progressive neurologic condition that causes motor and nonmotor manifestations. Treatment provides symptomatic benefit but no current treatment has been proven to slow disease progression. Research studies of PD require a means of rating the severity of disease by measurement of motor manifestations, assessment of ability to perform daily functional activities, and symptomatic response to medication. The most common rating scales are the Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr staging, and the Schwab and England rating of activities of daily living. Each of these rating scales are described, including detailed instructions on how to implement these ratings. Although these are the most widely applied rating scales of PD, there are still substantial limitations to these scales that must be considered when using them for research. Finally, some common applications of these scales are described. Curr. Protoc. Neurosci. 49:10.1.1‐10.1.14. © 2009 by John Wiley & Sons, Inc.

Keywords: Parkinson disease; rating scales; activities of daily living; clinical trials

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • The Scales
  • Applications of the Rating Scales
  • Acknowledgements
  • Literature Cited
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Literature Cited

Literature Cited
   Chan, P.L., Nutt, J.G., and Holford, N.H. 2004. Modeling the short‐ and long‐duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease. J. Pharmacokinet. Pharmacodyn. 31:243‐268.
   Chaudhuri, K.R., Healy, D.G., and Schapira, A.H. 2006. Non‐motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol. 5:235‐245.
   Fahn, S. 2003. Description of Parkinson's disease as a clinical syndrome. Ann. N.Y. Acad. Sci. 991:1‐14.
   Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C.W., Tanner, C., and Marek, K. 2004. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351:2498‐2508.
   Goetz, C. 2004. Re: UPDRS: Status and recommendations. Mov. Disord. 19:605.
   Goetz, C.G. and Stebbins, G.T. 2004. Assuring interrater reliability for the UPDRS motor section: Utility of the UPDRS teaching tape. Mov. Disord. 19:1453‐1456.
   Goetz, C.G., Stebbins, G.T., Chmura, T.A., Fahn, S., Klawans, H.L., and Marsden, C.D. 1995. Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov. Disord. 10:263‐266.
   Goetz, C.G., LeWitt, P.A., and Weidenman, M. 2003. Standardized training tools for the UPDRS activities of daily living scale: Newly available teaching program. Mov. Disord. 18:1455‐1458.
   Goetz, C.G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G.T., Counsell, C., Giladi, N., Holloway, R.G., Moore, C.G., Wenning, G.K., Yahr, M.D., and Seidl, L. 2004. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. Mov. Disord. 19:1020‐1028.
   Goetz, C.G., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stebbins, G.T., Stern, M.B., Tilley, B.C., Dodel, R., Dubois, B., Holloway, R., Jankovic, J., Kulisevsky, J., Lang, A.E., Lees, A., Leurgans, S., LeWitt, P.A., Nyenhuis, D., Olanow, W., Rascol, O., Schrag, A., Teresi, J.A., Van Hilten, J.J., and LaPelle, N. 2007. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan. Mov. Disord. 22:41‐47.
   Hershey, T., Black, K.J., Carl, J.L., McGee‐Minnich, L., Snyder, A.Z., and Perlmutter, J.S. 2003. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 74:844‐851.
   Hoehn, M.M. and Yahr, M.D. 1967. Parkinsonism: Onset, progression and mortality. Neurology 17:427‐442.
   Langston, J.W., Widner, H., Goetz, C.G., Brooks, D., Fahn, S., Freeman, T., and Watts, R. 1992. Core assessment program for intracerebral transplantations (CAPIT). Mov. Disord. 7:2‐13.
   Louis, E.D., Lynch, T., Marder, K., and Fahn, S. 1996. Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. Mov. Disord. 11:185‐192.
   Martinez‐Martin, P., Gil‐Nagel, A., Gracia, L.M., Gomez, J.B., Martinez‐Sarries, J., and Bermejo, F. 1994. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov. Disord. 9:76‐83.
   McColl, C.D., Reardon, K.A., Shiff, M., and Kempster, P.A. 2002. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov. Disord. 17:1227‐1234.
   Miyasaki, J.M., Shannon, K., Voon, V., Ravina, B., Kleiner‐Fisman, G., Anderson, K., Shulman, L.M., Gronseth, G., and Weiner, W.J. 2006. Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence‐based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:996‐1002.
   Nutt, J.G. and Woodward, W.R. 1986. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36:739‐744.
   Pahwa, R., Factor, S.A., Lyons, K.E., Ondo, W.G., Gronseth, G., Bronte‐Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., and Weiner, W.J. 2006. Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence‐based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:983‐995.
   Racette, B.A., Tabbal, S.D., Jennings, D., Good, L., Perlmutter, J.S., and Evanoff, B. 2005. Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology 64:230‐235.
   Racette, B.A., Tabbal, S.D., Jennings, D., Good, L.M., Perlmutter, J.S., and Evanoff, B.A. 2006. A rapid method for mass screening for parkinsonism. Neurotoxicology 27:357‐361.
   Rajput, A.H., Rozdilsky, B., and Rajput, A. 1991. Accuracy of clinical diagnosis in parkinsonism—A prospective study. Can. J. Neurol. Sci. 18:275‐278.
   Ramaker, C., Marinus, J., Stiggelbout, A.M., and Van Hilten, B.J. 2002. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov. Disord. 17:867‐876.
   van Hilten, J.J., van der Zwan, A.D., Zwinderman, A.H., and Roos, R.A. 1994. Rating impairment and disability in Parkinson's disease: Evaluation of the Unified Parkinson's Disease Rating Scale. Mov. Disord. 9:84‐88.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library